Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 18/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 17/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 17/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 17/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 14/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 2/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 1/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.73 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.73 |
| ▸ | INSR | P06213 | 1/20 | 0.73 |
| ▸ | CFTR | P13569 | 1/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.73 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491260 | 0.95 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL490953 | 0.90 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL13926127 | 0.87 | GSK3A (0.80) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL490878 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| Aloisine A SCHEMBL80147 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1777822 | 0.81 | GSK3A (0.72) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL6852911 | 0.81 | GSK3A (0.67) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1777268 | 0.80 | GSK3A (0.69) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| Iodide SCHEMBL1779435 | 0.80 | GSK3A (0.69) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL491113 | 0.80 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713433-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | Children's Hospital Medical Center (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4689067-A2 | CLINICAL-GRADE ORGANOIDS | Children's Hospital Medical Center (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2024238977-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4440586-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | Children's Hospital Medical Center (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2024206911-A2 | CLINICAL-GRADE ORGANOIDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240318146-A1 | VASCULARIZED ORGANOIDS | CHILDREN’S HOSPITAL MEDICAL CENTER (US) | 2024-09-26 | — | — | US | claimed |
| EP-4388083-A1 | VASCULARIZED ORGANOIDS | Children's Hospital Medical Center (US) | 2024-06-26 | — | — | EP | claimed |
| US-20240148835-A1 | TREATING DISORDERS ASSOCIATED WITH DYRK1A DYSFUNCTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-09 | — | — | US | claimed |
| WO-2023102133-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023023180-A1 | VASCULARIZED ORGANOIDS | CHILDREN’S HOSPITAL MEDICAL CENTER (US) | 2023-02-23 | — | — | WO | claimed |
| US-20220275341-A1 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | CHILDRENS HOSPITAL MED CT (US) | 2022-09-01 | — | — | US | claimed |
| WO-2022165250-A1 | TREATING DISORDERS ASSOCIATED WITH DYRK1A DYSFUNCTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-08-04 | — | — | WO | claimed |
| EP-4022036-A2 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | Children's Hospital Medical Center, Center for Technology Commercialization (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114430774-A | Organoid mesoderm lineage diversification | 儿童医院医学中心 | 2022-05-03 | — | — | CN | claimed |
| EP-4731750-A2 | METHODS OF MATRIX-FREE SUSPENSION CULTURE | Children's Hospital Medical Center (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720258-A1 | HUMAN GASTROINTESTINAL ORGANOIDS, METHODS OF PRODUCING SAME, AND USES THEREOF | Valorisation-HSJ, Limited Partnership (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-1619503-A1 | Use of standards for monitoring alterations of peptide and protein samples | BioVisioN AG (DE) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006005622-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BIOVISION GMBH (DE) | 2006-01-19 | — | — | WO | disclosed |
| EP-1388541-A1 | Pyrrolopyrazines as kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | GSK3A 3577/4885GSK3B 3915/4885CDK1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.